Michael Nagler
www.mendeley.com
0000-0003-4319-2367
9 papers found
Refreshing results…
Determination of Anti-Xa Inhibitor Plasma Concentrations Using a Universal Edoxaban Calibrator
A machine-learning model for reducing misdiagnosis in heparin-induced thrombocytopenia: a prospective, multicenter, observational study
Long‐term safety of the stem cell releasing compound plerixafor for peripheral stem cell collection in myeloma patients
Prothrombinase-Induced Clotting Time to Measure Drug Concentrations of Rivaroxaban, Apixaban, and Edoxaban in Clinical Practice: A Cross-Sectional Study
A universal anti‐Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation
Immunoadsorption for the treatment of acquired hemophilia: new observational data, systematic review and meta-analysis
Accuracy of serological testing for SARS‐CoV‐2 antibodies: first results of a large mixed‐method evaluation study
A high Gas6 level in plasma predicts venous thromboembolism recurrence, major bleeding and mortality in the elderly: a prospective multicenter cohort study
Epistaxis in anticoagulated patients: Fewer hospital admissions and shorter hospital stays on rivaroxaban compared to phenprocoumon
Missing publications? Search for publications with a matching author name.